SomaGenics Inc.

19 articles about SomaGenics Inc.

• SomaGenics' Strengthens Its IP and Technology Position in Small RNA Analysis and Biomarker Discovery With New Patent and Publication

  9/18/2018

  SomaGenics announced today the issue of US Patent 10,041,107, a continuation of SomaGenics' patent family entitled "Methods and Compositions for Detection of small RNAs."

• SomaGenics Awarded Multi-Year Funding for Hepatitis Delta Virus Therapeutic Program

  7/30/2018

  SomaGenics, Inc. announces the award of a three-year, $2.9 million NIH grant in support of its Hepatitis Delta Virus (HDV) therapeutic program under Principal Investigator and SomaGenics CEO Brian H. Johnston, Ph.D.

• SomaGenics Launches Its RealSeq®-biofluids Kit and Advances Liquid Biopsy Development With New NIH Funding for cf-miRNA NGS Technology

  5/22/2018

  SomaGenics announced the launch of RealSeq®-biofluids, a next-generation sequencing (NGS) library construction kit sensitive enough to detect small RNAs from cell-free biofluids. Further enhancing its efforts in the liquid biopsy arena, SomaGenics has received a 3-year Phase II SBIR grant from the NIH for the development of RealSeq®-T, a technology enabling extraction-free, targeted NGS of small RNAs directly from biofluids.

• SomaGenics Announces Upcoming Data Presentations of Its Wound Healing Therapeutic Program

  4/24/2018

  SomaGenics, Inc. today announced two forthcoming presentations and a publication on preclinical results of its wound healing therapeutic program

• SomaGenics Receives Award or Allowance of Four Patents Covering Its Small RNA Analysis and Therapeutics

  12/19/2017

  A patent covering RealSeq-T was also allowed by the European Patent Office.

• SomaGenics Inc. Awarded NIH Funding To Develop NGS Single-Cell Analysis Of Small RNAs

  10/10/2017

• SomaGenics Inc. Awarded NIH Funding To Develop Novel Cell-Free-DNA Liquid Biopsy Platform

  5/25/2017

• SomaGenics Inc. To Present At The Symposium On Advanced Wound Care And Wound Healing Society

  4/4/2017

• SomaGenics Inc. Granted New Patents For RNA Detection And RNA-Based Therapeutics Technologies

  11/29/2016

• SomaGenics Inc. Secures $1.8M In Funding From NIH To Further Develop The Real-Seq Technology Platform

  10/4/2016

• Rubicon Genomics Licenses Commercialization Rights From SomaGenics Inc. For Its RealSeq-AC Technology For High-Throughput Sequencing Of Small RNA's

  7/28/2016

• SomaGenics Inc. Awarded Second NIH Grant To Develop resQ-RNA Technology To Quantify Fragmented mRNA From Degraded Samples

  2/9/2016

• SomaGenics Inc. Launches miR-ID Platform And Assays For Highly Sensitive And Specific Quantification Of microRNAs (miRNAs)

  10/7/2015

• SomaGenics Inc. Awarded 2-Year NIH Grant To Develop NGS microRNA Library Technology

  4/28/2015

• Three SomaGenics Inc. Publications Demonstrate Successful Inhibition Of The Hepatitis C Virus By Therapeutic sshRNA And Confirm Mechanism Of Action

  12/19/2014

• SomaGenics Inc. Awarded Four Patents Spanning Its miRNA And RNAi Programs

  12/16/2014

• SomaGenics Inc. Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation National Institutes of Health (NIH) Grants

  11/12/2012

• SomaGenics Inc. Reports Study on Mechanism of Action of Its Therapeutic Platform

  7/24/2012

• SomaGenics Inc.' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus

  9/20/2011